Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 4 |
2023 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Did you mean
titenko k[Author]
(14 results)?
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Leukemia. 2021 Feb;35(2):440-453. doi: 10.1038/s41375-020-01111-2. Epub 2021 Jan 7.
Leukemia. 2021.
PMID: 33414482
Free PMC article.
Clinical Trial.
The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study.
Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Patterson BC, Samis J, Izquierdo M, Titorenko K, Li S, Sosothikul D.
Hijiya N, et al. Among authors: titorenko k.
Blood Adv. 2023 Dec 12;7(23):7279-7289. doi: 10.1182/bloodadvances.2023010122.
Blood Adv. 2023.
PMID: 37738125
Free PMC article.
Item in Clipboard
A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.
Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Patterson B, Samis J, Aimone P, Allepuz A, Titorenko K, Sosothikul D.
Hijiya N, et al. Among authors: titorenko k.
Blood Adv. 2021 Jul 27;5(14):2925-2934. doi: 10.1182/bloodadvances.2020003759.
Blood Adv. 2021.
PMID: 34309636
Free PMC article.
Clinical Trial.
Item in Clipboard
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
Radich JP, Hochhaus A, Masszi T, Hellmann A, Stentoft J, Casares MTG, García-Gutiérrez JV, Conneally E, le Coutre PD, Gattermann N, Martino B, Saussele S, Giles FJ, Ross DM, Aimone P, Li S, Titorenko K, Saglio G.
Radich JP, et al. Among authors: titorenko k.
Leukemia. 2021 May;35(5):1344-1355. doi: 10.1038/s41375-021-01205-5. Epub 2021 Mar 11.
Leukemia. 2021.
PMID: 33707652
Free PMC article.
Clinical Trial.
Item in Clipboard
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Zanichelli M, Bendit I, Cacciatore S, Titorenko K, Aimone P, Saglio G, Hochhaus A.
Kantarjian HM, et al. Among authors: titorenko k.
Leukemia. 2021 Jul;35(7):2142-2143. doi: 10.1038/s41375-021-01306-1.
Leukemia. 2021.
PMID: 34108614
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite